TAGLN2 exerts a pro-PAH effect via immune (HLA DR+ monocytes) and metabolic (cysteinylglycine disulfide, eicosenedioate) pathways, highlighting its potential pleiotropic roles in various pathological stages. The gene discussed is TAGLN2; the disease is pulmonary arterial hypertension.